Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HK2 | P52789 | 5/20 | 0.50 |
| ▸ | HK1 | P19367 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19477925 | 1.00 | PYGB (0.64) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL15334409 | 1.00 | PYGB (0.64) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL29906478 | 1.00 | PYGB (0.64) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL28790741 | 1.00 | PYGB (0.64) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL18193284 | 1.00 | PYGB (0.64) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL15334407 | 1.00 | PYGB (0.64) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL24943581 | 1.00 | PYGB (0.64) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL29574842 | 1.00 | PYGB (0.64) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL15046974 | 1.00 | PYGB (0.64) | PYGBGAAKDM4ELMNACYP2D6 | |
| SCHEMBL17215084 | 1.00 | PYGB (0.64) | PYGBGAAKDM4ELMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257764-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | SYNAFFIX B.V. (NL) | 2016-09-08 | — | — | US | disclosed |
| US-20160235861-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | SynAffix. B.V. (NL) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257764-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | FUT5, FCGR1A, FCGR3B | PYGB 1513/4885GAA 113/4885KDM4E 2011/4885 |
| US-20160235861-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | FCGR1A, FCGR3B, FCGR2A | PYGB 1088/4885GAA 93/4885KDM4E 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.